MERKEZİMİZE BAŞVURAN NONVALVÜLER ATRİYAL FİBRİLASYONLU HASTALARIN DEMOGRAFİK ÖZELLİKLERİNİN VE ORAL ANTİKOAGÜLASYON TERCİHLERİNİN RETROSPEKTİF OLARAK DEĞERLENDİRİLMESİ Retrospective Evaluation of Oral Anticoagulation Preferences and Demographic Characteristics of the Patients with Nonvalvular Atrial

Amaç: Atriyal fibrilasyon (AF) en sık saptanan kardiyak aritmi olup tromboembolik olay oranında 5 kat artış-la ilişkilidir. Yozgat popülasyonunda non-valvüler AF nedeniyle hastaneye başvuru sıklığı, risk faktörlerininvarlığı, uygulanan antikoagülan–antitrombotik tedavinin seçimi hakkında literatürde yeterli veri yoktur. Buçalışmada, Yozgat ilinde yaşayan non-valvüler AF’li hastaların demografik özelliklerini, antikoagülan–antit-rombotik tedavi seçimini ve iskemik inme gelişim riskini değerlendirmeyi amaçladık.Metod: Bozok Üniversitesi Tıp Fakültesi Hastanesi Kardiyoloji polikliniğine başvuran 18 yaş üstü non-valvüler AF tanılı 316 kişinin bilgileri retrospektif olarak incelendi. Hastaların bazal demografik verileri, inmerisk faktörleri ve kullanmış oldukları antiagregan–antikoagülan tedavileri değerlendirildi.Bulgular: Hastaların 130’u (%41) erkek ve 186’sı (%59) kadın bireylerden oluşmaktaydı. Hastaların yaş orta-laması 67,5±12,9 yıldı. Ortalama CHA2DS2-VASC skoru 3,2±1,3 olarak bulundu. AF’ye eşlik eden inme riskfaktörleri sıklık sırasına göre yaş, hipertansiyon, vasküler hastalıklar, kalp yetmezliği ve diyabetes mellitusolarak bulundu.Sonuç: Hastaların büyük çoğunluğunun oral antikoagülan (OAK) kullandığı gözlenmiştir. Fakat hala azım-sanmayacak şekilde OAK tedavisi almayan ya da eksik tedavi alan hastalarında olduğu da tespit edilmiştir.

Retrospective Evaluation of Oral Anticoagulation Preferences and Demographic Characteristics of the Patients with Nonvalvular Atrial Fibrillation in Our Center

Objectives: Atrial fibrillation (AF) is the most commonly detected arrhythmia and is associated with a 5-fold increase in thromboembolic event rate. There is insufficient data in the literature about the frequency of referral to the hospital due to non-valvular AF, the presence of risk factors, and the choice of applied anticoagulant-antithrombotic treatment in the Yozgat population. In this study, we aimed to evaluate the demographic characteristics, the choice of anticoagulant-antithrombotic treatment, and the risk factors for ischemic stroke of the patients with non-valvular AF in Yozgat province. Methods: This was a single center retrospective study. The cases were consecutive AF patients, who were followed-up by the Cardiology outpatient clinic of Bozok University, Faculty of Medicine. A total of 316 non-valvular AF patients over 18 years old, were retrospectively evaluated. Baseline demographic characteristics, stroke risk factors and the data of antiplatelet and anticoagulant therapy were recorded. Results: One-hundred-thirty (41%) of the patients were male and 186 (59%) were female. The mean age of the patients was 67,5±12,9 years. The mean CHA2DS2-VASC score was found to be 3.2 ± 1.3. The most common stroke risk factors associated with AF were; age, hypertension, vascular diseases, heart failure and diabetes mellitus, respectively. Conclusion: We report that the vast majority of patients use oral anticoagulants (OAC), but, unfortunately it has also been found that, there are a considerable number of patients who are still not treated or receive incomplete treatment.

PDF

___

Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A, et al. Projections on the number of individuals with atrial fibril- lation in the European Union, from 2000 to 2060. EurHeart J. 2013;34(35):2746–51.
Macle L, Cairns J, Leblanc K, Tsang T, Skanes A, Cox JL et al. CCS Atrial Fibrillation Guidelines Committee. 2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Manage- ment of Atrial Fibrillation. Can J Cardiol. 2016 Oct;32(10):1170-85.
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, OldgrenJ , Parekh A, et al. RE-LY Steering Committee and Investigators. Dabiga- tran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.
. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvu- lar atrial fibrillation. N Engl J Med. 2011;365(10):883–91.
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104.
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 Feb;137(2):263-72.
Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH,et al. ESC Committee for Practice Guidelines (CPG). 2012 ocused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the manage- ment of atrial fibrillation. Developed with the special contribu- tion of the European Heart Rhythm Association. EurHeart J. 2012 Nov;33(21):2719-47.
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B,et al. 2016 ESC Guidelines for the management of atrial fibril- lation developed in collaboration with EACTS. EurHeart J. 2016 Oct7;37(38):2893-962. Epub 2016 Aug 27.
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an indepen- dent risk factor for stroke: the Framingham Study. Stroke. 1991; 22: 983-8.
Healey JS, Connolly SJ. Atrial Fibrillation: Hypertension as a Causative Agent, Risk Factor for Complications, and Potential Thera- peutic Target. Am J Cardiol. 2003; 91: 9-14.
12. Mason PK, Lake DE, DiMarco JP, Ferguson JD, Mangrum JM, Bilchick K,et al. Impact of the CHA2DS2-VASc score on anticoagu- lation recommendations for atrial fibrillation. Am J Med. 2012 Jun;125(6):603.e1-6.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W,et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvu- lar atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883-91.
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Hal- perin JL,et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28;369(22):2093-104.
Halvorsen S, Atar D, Yang H,De Caterina R, Erol C, Garcia D, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014 Jul 21;35(28):1864-72.
Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Randomized Evaluation of Long-Term Anticoagulation Therapy In- vestigators. Newly identified events in the RE-LY trial. N Engl J Med. 2010 Nov 4;363(19):1875-6.
Başaran Ö, Beton O, Doğan V, Tekinalp M, Aykan AÇ, et al; ReAl-life Multicenter Survey Evaluating Stroke prevention strategies in non-valvular atrialfibrillation (RAMSES study). Anatol J Cardiol. 2016 Oct;16(10):734-41.
Ertas F, Eren NK, Kaya H, Aribas A, Acar G, Kanadasi M,et al. AFTER Investigators. The atrial fibrillation in Turkey: Epidemiologic Registry (AFTER). Cardiol J. 2013;20(4):447-52.
Kaya H, Ertas F, Koroglu B, Vatan B, Cagliyan CE, Gedik S, et al. Predictors of anticoagulant treatment in patients with nonvalvular atrial fibrillation: results from atrial fibrillation in Turkey: epidemio- logic registry. Clin Appl Thromb Hemost. 2015;21:144–8.
Connolly S, PogueJ, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised con- trolled trial. Lancet. 2006; 367: 1903-12.